Proteomic serum biomarkers and their potential application in cancer screening programs.

Abstract

Early diagnosis of cancer is of pivotal importance to reduce disease-related mortality. There is great need for non-invasive screening methods, yet current screening protocols have limited sensitivity and specificity. The use of serum biomarkers to discriminate cancer patients from healthy persons might be a tool to improve screening programs. Mass spectrometry based proteomics is widely applied as a technology for mapping and identifying peptides and proteins in body fluids. One commonly used approach in proteomics is peptide and protein profiling. Here, we present an overview of profiling methods that have the potential for implementation in a clinical setting and in national screening programs.

• Authors: Anouck Huijbers, Berit Velstra, Tim J A Dekker, Wilma E Mesker, Yuri E M van der Burgt, Bart J Mertens, André M Deelder, Rob A E M Tollenaar
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 11 Issue 11 Pg. 4175-93 (Oct 26 2010) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 21151433 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers, Tumor
• Neoplasm Proteins

Topics

• Biomarkers, Tumor (blood)
• Breast Neoplasms (blood)
• Colorectal Neoplasms (blood)
• Early Detection of Cancer (methods)
• Female
• Humans
• Male
• Neoplasm Proteins (blood)
• Proteomics (methods)